Drug discovery and development for spinal muscular atrophy: Lessons from screening approaches and future challenges for clinical development

Future Medicinal Chemistry

Volumn 2, Issue 9, 2010, Pages 1429-1440

  Pruss, Rebecca M ^a   Giraudon Paoli, Marc ^a   Morozova, Svetlana ^b   Berna, Patrick ^a   Abitbol, Jean Louis ^a   Bordet, Thierry ^a  

^a Trophos   (France)

^b Immunotech   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 PHENYLBUTYRIC ACID; ANTIBIOTIC AGENT; D 157495; HISTONE DEACETYLASE INHIBITOR; NEUROPROTECTIVE AGENT; OLESOXIME; PANOBINOSTAT; PTK SMA1; QUINAZOLINE; RILUZOLE; ROMIDEPSIN; SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 2; TC 007; TETRACYCLINE; TRO 19622; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SCREENING TEST; SPINAL MUSCULAR ATROPHY; UNSPECIFIED SIDE EFFECT;

DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MUSCULAR ATROPHY, SPINAL;

EID: 77956578919     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.228     Document Type: Review

References (84)

1. Pearn J. Incidence, prevalence and gene frequency studies of chronic childhood spinal muscular atrophy. J. Med. Genet. 15, 409-413 (1978).
2. McAndrew PE, Parsons DW, Simard LR et al. Identifcation of proximal spinal muscular atrophy carriers and patients by ana lysis of SMNT and SMNC gene copy number. Am. J. Hum. Genet. 60(6), 1411-1422 (1997).
3. Scheffer H, Cobben JM, Mensink RG, Stulp R P, van der Steege G, Buys CH. SMA carrier testing-validation of hemizygous SMN exon 7 deletion test for the identifcation of proximal spinal muscular atrophy carriers and patients with a single allele deletion. Eur. J. Hum. Genet. 8(2), 79-86 (2000).
4. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70(2), 358-368 (2002).
5. Hirtz D, Iannaccone S, Heemskerk J, Gwinn-Hardy K, Moxley R 3rd, Rowland LP. Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology 65(9), 1352-1357 (2005).
6. Dubowitz V. Muscle disorders in childhood. Major Probl. Clin. Pediatr. 16(iii-xiii), 1-282 (1978).
7. Kariya S, Park GH, Maeno-Hikichi Y et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17(16), 2552-2569 (2008).
8. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 96(11), 6307-6311 (1999).
9. Monani UR, Lorson CL, Parsons DW et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8(7), 1177-1183 (1999).
10. Gilliam TC, Brzustowicz LM, Castilla LH et al. Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature 345, 823-825 (1990).
11. Melki J, Lefebvre S, Burglen L et al. De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Science 264(5164), 1474-1477 (1994). (Pubitemid 24217141)
12. Lefebvre S, Burglen L, Reboullet S et al. Identifcation and characterization of a spinal muscular atrophy-determining gene. Cell 80(1), 155-165 (1995).
13. Spiegel R, Hagmann A, Boltshauser E, Moser H. Molecular genetic diagnosis and deletion ana lysis in type I-III spinal muscular atrophy. Schweiz. Med. Wochenschr. 126(21), 907-914 (1996).
14. Brahe C, Bertini E. Spinal muscular atrophies: recent insights and impact on molecular diagnosis. J. Mol. Med. 74(10), 555-562 (1996).
15. Coovert DD, Le TT, McAndrew PE et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6(8), 1205-1214 (1997).
16. Lefebvre S, Burlet P, Liu Q et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265-269 (1997).
17. Wirth B, Brichta L, Schrank B et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum. Genet. 119(4), 422-428 (2006).
18. Hsieh-Li HM, Chang JG, Jong YJ et al. A mouse model for spinal muscular atrophy. Nat. Genet. 24(1), 66-70 (2000).
19. Monani UR, Sendtner M, Coovert DD et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9(3), 333-339 (2000).
20. Michaud M, Arnoux T, Bielli S et al. Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy. Neurobiol. Dis. 38(1), 125-135 (2010).
21. Paushkin S, Gubitz AK, Massenet S, Dreyfuss G. The SMN complex, an assemblyosome of ribonucleoproteins. Curr. Opin. Cell Biol. 14(3), 305-312 (2002).
22. Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 15, 3555-3565 (1996).
23. Ross oll W, Kroning AK, Ohndorf UM, Steegborn C, Jablonka S, Sendtner M. Specifc interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons? Hum. Mol. Genet. 11(1), 93-105 (2002).
24. Zhang HL, Pan F, Hong D, Shenoy SM, Singer RH, Bassell GJ. Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J. Neurosci. 23(16), 6627-6637 (2003).
25. Rossoll W, Jablonka S, Andreassi C et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of b-actin mRNA in growth cones of motoneurons. J. Cell Biol. 163(4), 801-812 (2003).
26. McWhorter ML, Monani UR, Burghes AH, Beattie CE. Knockdown of the survival motor neuron (Smn) protein in zebrafsh causes defects in motor axon outgrowth and pathfnding. J. Cell Biol. 162(5), 919-931 (2003).
27. Oprea GE, Krober S, McWhorter ML et al. Plastin 3 is a protective modifer of autosomal recessive spinal muscular atrophy. Science 320(5875), 524-527 (2008).
28. Tsai MS, Chiu YT, Wang SH, Hsieh-Li HM, Lian WC, Li H. Abolishing Bax-dependent apoptosis shows benefcial effects on spinal muscular atrophy model mice. Mol. Ther. 13(6), 1149-1155 (2006).
29. Tsai LK, Tsai MS, Ting CH, Wang SH, Li H. Restoring Bcl-x(L) levels benefts a mouse model of spinal muscular atrophy. Neurobiol. Dis. 31(3), 361-367 (2008).
30. Hauke J, Riessland M, Lunde S et al. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum. Mol. Genet. 18(2), 304-317 (2009).
31. Burlet P, Huber C, Bertrandy S et al. The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Hum. Mol. Genet. 7(12), 1927-1933 (1998).
32. Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci. 10(8), 597-609 (2009).
33. Chan YB, Miguel-Aliaga I, Franks C et al. Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum. Mol. Genet. 12(12), 1367-1376 (2003).
34. Rajendra TK, Gonsalvez GB, Walker MP, Shpargel KB, Salz HK, Matera AG. A Drosophila melanogaster model of spinal muscular atrophy reveals a function for SMN in striated muscle. J. Cell Biol. 176(6), 831-841 (2007).
35. Chang HC, Dimlich DN, Yokokura T et al. Modeling spinal muscular atrophy in Drosophila. PLoS ONE, 3(9), e3209 (2008).
36. Cifuentes-Diaz C, Frugier T, Tiziano FD et al. Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy. J. Cell Biol. 152(5), 1107-1114 (2001).
37. Le TT, Pham LT, Butchbach ME et al. SMND7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14(6), 845-857 (2005).
38. Gavrilina TO, McGovern VL, Workman E et al. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specifc SMN expression has no phenotypic effect. Hum. Mol. Genet. 17(8), 1063-1075 (2008).
39. Bordet T, Buisson B, Michaud M et al. Identifcation and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 322(2), 709-720 (2007).
40. Bordet T, Buisson B, Michaud M et al. Specifc antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J. Pharmacol. Exp. Ther. 326(2), 623-632 (2008).
41. Xiao WH, Zheng FY, Bennett GJ, Bordet T, Pruss RM. Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain 147(1-3), 202-209 (2009).
42. Bordet T, Berna P, Abitbol JL, Pruss RM. Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals 3, 345-368 (2010).
43. Rovini A, Carré M, Bordet T, Pruss RM, Braguer, D. Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem. Pharmacol. 80(6), 884-894 (2010).
44. Bowerman M, Beauvais A, Anderson CL, Kothary R. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 19(8), 1468-1478 (2010).
45. Kernochan LE, Russo ML, Woodling NS et al. The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 14(9), 1171-1182 (2005).
46. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl Acad. Sci. USA 98(17), 9808-9813 (2001).
47. Brichta L, Hofmann Y, Hahnen E et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 12(19), 2481-2489 (2003).
48. Sumner CJ, Huynh TN, Markowitz JA et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54(5), 647-654 (2003).
49. Andreassi C, Angelozzi C, Tiziano FD et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 12(1), 59-65 (2004).
50. Riessland M, Brichta L, Hahnen E, Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, signifcantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. 120(1), 101-110 (2006).
51. Mercuri E, Bertini E, Messina S et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy Neurology 68(1), 51-55 (2007).
52. Swoboda KJ, Scott CB, Reyna SP et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS ONE, 4(5), e5268 (2009).
53. Garbes L, Riessland M, Holker I et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum. Mol. Genet. 18(19), 3645-3658 (2009).
54. Jarecki J, Chen X, Bernardino A et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet. 14(14), 2003-2018 (2005).
55. Butchbach ME, Singh J, Thorsteinsdottir M et al. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum. Mol. Genet. 19(3), 454-467 (2010).
56. Singh J, Salcius M, Liu SW et al. DcpS as a therapeutic target for spinal muscular atrophy. ACS Chem. Biol. 3(11), 711-722 (2008).
57. Grzeschik SM, Ganta M, Prior TW, Heavlin WD, Wang CH. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann. Neurol. 58(2), 194-202 (2005).
58. Hastings ML, Berniac J, Liu YH et al. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy Sci. Transl. Med. 1(5), 5ra12 (2009).
59. Wolstencroft EC, Mattis V, Bajer AA, Young PJ, Lorson CL. A non-sequence-specifc requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum. Mol. Genet. 14(9), 1199-1210 (2005).
60. Heier CR, DiDonato CJ. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum. Mol. Genet. 18(7), 1310-1322 (2009).
61. Chang CW, Hui Y, Elchert B, Wang J, Li J, Rai R. Pyranmycins, a novel class of aminoglycosides with improved acid stability: the SAR of D-pyranoses on ring III of pyranmycin. Org. Lett. 4(26), 4603-4606 (2002).
62. Mattis VB, Ebert AD, Fosso MY, Chang CW, Lorson CL. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum. Mol. Genet. 18(20), 3906-3913 (2009).
63. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specifc activators. Nat. Struct. Biol. 10(2), 120-125 (2003).
64. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fbroblasts. Proc. Natl Acad. Sci. USA 100(7), 4114-4119 (2003).
65. Dickson A, Osman E, Lorson CL. A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Hum. Gene. Ther. 19(11), 1307-1315 (2008).
66. Meyer K, Marquis J, Trub J et al. Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum. Mol. Genet. 18(3), 546-555 (2009).
67. Williams JH, Schray RC, Patterson CA, Ayitey SO, Tallent MK, Lutz GJ. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci. 29(24), 7633-7638 (2009).
68. Baughan TD, Dickson A, Osman EY, Lorson CL. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum. Mol. Genet. 18(9), 1600-1611 (2009).
69. Singh RN. Evolving concepts on human SMN pre-mRNA splicing. RNA Biol. 4(1), 7-10 (2007).
70. Foust KD, Wang X, McGovern VL et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28(3), 271-274 (2010).
71. Passini MA, Bu J, Roskelley EM et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest. 120(4), 1253-1264 (2010).
72. Valori CF, Ning K, Wyles M et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2(35), 35ra42 (2010).
73. Riessland M, Ackermann B, Forster A et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet. 19(8), 1492-1506 (2010).
74. Barois A, Mayer M, Desguerre I et al. Spinal muscular atrophy. A 4-year prospective, multicenter, longitudinal study (168 cases). Bull. Acad. Natl Med. 189(6), 1181-1198; discussion 1198-11189 (2005).
75. Swoboda KJ, Prior TW, Scott CB et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann. Neurol. 57(5), 704-712 (2005).
76. Millino C, Fanin M, Vettori A et al. Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy. BMC Med. 7, 14 (2009).
77. Brahe C, Vitali T, Tiziano FD et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 13(2), 256-259 (2005).
78. Brichta L, Holker I, Haug K, Klockgether T, Wirth B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. 59(6), 970-975 (2006).
79. Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur. J. Paediatr. Neurol. 7(4), 155-159 (2003).
80. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modifed Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul. Disord. 16(7), 417-426 (2006).
81. Berard C, Payan C, Fermanian J, Girardot F. A motor function measurement scale for neuromuscular diseases-description and validation study. Rev. Neurol. (Paris) 162(4), 485-493 (2006).
82. Mercuri E, Messina S, Battini R et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul. Disord. 16(2), 93-98 (2006).
83. Glanzman AM, Mazzone E, Main M et al. The Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul. Disord. 20(3), 155-161 (2010).
84. Lunn MR, Root DE, Martino AM et al. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism.Chem Biol. 11(11), 1489-1493 (2004).